The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
In the first few months of the coronavirus disease 2019 (COVID-19) pandemic, mammography screenings dropped drastically and patients with breast cancer presented with more advanced and aggressive disease, according to study findings presented at the 2020 San Antonio Breast Cancer Symposium.
The retrospective, double-cohort study observed patients visiting the Kaiser Permanente health care system, comparing those who visited the health system between March 17 and May 18, 2020—during California’s shelter-in-place period—to those who visited the health system between March and May 2019.
“The COVID-19 pandemic drove operational changes in Kaiser Permanente California,” said Annie Tang, MD, researcher at Kaiser Permanente Northern California’s Permanente Medical Group Breast Research Collaborative. She said that on March 17, 2020, when the California shelter-in-place order was initiated, “Breast cancer guidelines were developed within our large integrated health care system of 22 hospitals, all outreach for mammography screenings were held, but women who wished to have screening were still accommodated, elective surgeries were stopped, and cancer surgeries were continued.”
There were 703 patients with newly diagnosed disease identified in the 2019 period, compared with 250 during the shelter-in-place period, representing a 64% drop in the number of patients who received a diagnosis and potentially highlighting that there were 453 patients who had undiagnosed disease during this time, Tang said.
Both groups of patients had similar baseline characteristics, although there were significantly more patients in the 2020 period who presented with symptomatic disease (78% vs 37%) and presented with more advanced disease, as measured by >T1c tumors (78% vs 64%; P < .001), positive nodal status (24% vs 18%; P = .07), and metastatic disease (7% vs 2%; P = .002).
Patients in 2020 also had tumors of more aggressive receptor subtypes. More patients in 2020 had hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) disease (13% vs 9%) and HR-negative (HR-)/HER2-negative (HER2-) disease (16% vs 10%), while they had less HR+/HER2- disease (66% vs 76%) and less HR-/HER2+ disease (4% vs 5%).
“As screening mammography rates return to prepandemic levels, our system must prepare for a likely surge of new breast cancer diagnoses,” Tang said. “We will continue to monitor breast cancer screening rates, breast cancer diagnosis, and treatment trends for future research.”
Although the majority of initial treatment was surgery for both 2020 and 2019, the percentage of patients getting surgery decreased in 2020 (71% vs 83%) as the percentage of patients getting chemotherapy as initial treatment increased (15% vs 10%). More patients also underwent neoadjuvant hormone therapy in 2020 (5% vs 0%).
Notably, the time to first treatment was shorter in 2020, with time to surgery dropping from 26 to 19 days and time to chemotherapy dropping from 28 to 24 days.
Reference
1. Chang S, Savitz A, Vuong B, et al. Characterization of breast cancer management during the COVID 19 pandemic in a large integrated healthcare delivery system: Stage at diagnosis and timing/modality of first treatment. Presented at: San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract SS2-06. https://www.abstractsonline.com/pp8/#!/9223/presentation/704
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More